Magnetic resonance spectroscopy of the brain

Postgraduate Medical Journal

Volumn 89, Issue 1048, 2013, Pages 94-106

  Currie, Stuart ^a   Hadjivassiliou, Marios ^b   Craven, Ian J ^a   Wilkinson, Iain D ^a   Griffiths, Paul D ^a   Hoggard, Nigel ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID;

ALZHEIMER DISEASE; BRAIN DYSFUNCTION; BRAIN TUMOR; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; REVIEW; SIGNAL NOISE RATIO; SYSTEMATIC REVIEW (TOPIC);

BRAIN; BRAIN DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEURODEGENERATIVE DISEASES; REPRODUCIBILITY OF RESULTS;

EID: 84872912580     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-130471     Document Type: Review

References (141)

1. Ridgway JP. Cardiovascular magnetic resonance physics for clinicians: part I. J Cardiovasc Magn Reson 2010;12:71.
2. Jacobs MA, Ibrahim TS, Ouwerkerk R. AAPM/RSNA physics tutorials for residents: MR imaging: brief overview and emerging applications. Radiographics 2007;27:1213-29.
3. Rosen Y, Lenkinski R. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics 2007;4:330-45.
4. vander Graaf M. In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J 2010;39:527-40.
5. Drost DJ, Riddle WR, Clarke GD. Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med Phys 2002;29:2177-97.
6. Hoffman RE. Standardization of chemical shifts of TMS and solvent signals in NMR solvents. Magn Reson Chem 2006;44:606-16.
7. McRobbie D, Moore E, Graves M, et al. Welcome to the MR unit. In: McRobbie D, Moore E, Graves M, et al., eds. MRI from picture to proton. 2nd edn. Cambridge: Cambridge University Press, 2007:13.
8. Miller B. A Review of chemical issues in 1H NMR spectroscopy: N-Acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4:47-52.
9. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001;265:54-84.
10. Moffett J, Ross B, Arun P, et al. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007;81:89-131.
11. Mountford C, Stanwell P, Lin A, et al. Neurospectroscopy: the past, present and future. Chem Rev 2010;110:3060-86.
12. Signoretti S, Marmarou A, Tavazzi B, et al. N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. J Neurotrauma 2001;18:977-91.
13. Tallen H, Moore S, Stein W. Studies on the free amino acids and related compounds in the tissues of the cat. J Biol Chem 1954;211:927-39.
14. Verbalis JG. Control of brain volume during hypoosmolality and hyperosmolality. Adv Exp Med Biol. 2006;576:113-29; discussion 361-3.
15. Zhao J, Ramadan E, Cappiello M, et al. NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. Eur J Neurosci 2001;13:340-6.
16. Namboodiri AM, Moffett JR, Arun P, et al. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease. Adv Exp Med Biol 2006;576:145-63; discussion 361-3.
17. Namboodiri AM, Peethambaran A, Mathew R, et al. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol Cell Endocrinol 2006;252:216-23.
18. Rubaek E, Ross B. Magnetic resonance spectroscopy diagnosis of neurological disease. New York: Marcel Dekker, 1999.
19. Hajek M, Dezortova M. Introduction to clinical in vivo MR spectroscopy. Eur J Radiol 2008;67:185-93.
20. Lowry O, Berger S, Chi M, et al. Diversity of metabolic patterns in human brain tumours-I. High energy phosphate compounds and basic composition. J Neurochem 1977;29:959-77.
21. Li B, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging 2003;21:923-8.
22. Hanefeld F, Holzbach U, Kruse B, et al. Diffuse white matter disease in three children: an encephalopathy with unique features on magnetic resonance imaging and proton magnetic resonance spectroscopy. Neuropediatrics 1993;24:244-8.
23. Soares D, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 2009;64:12-21.
24. Castillo M, Kwock L, Mukherji S. Clinical applications of proton MR spectroscopy. Am J Radiol 1996;17:1-15.
25. Gill SS, Small RK, Thomas DG, et al. Brain metabolites as 1H NMR markers of neuronal and glial disorders. NMR Biomed 1989;2:196-200.
26. Font C, Garia-Campos M, Hansen AJ, et al. Simultaneous diffusion of inositol and mannitol in the rat brain. Rev Esp Fisiol 1982;38:317-19.
27. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289-98.
28. Castillo M, Kwock L, Scatliff J, et al. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am 1998;6:1-20.
29. Strange K, Emma F, Paredes A, et al. Osmoregulatory changes in myo-inositol content and Na+/myo-inositol cotransport in rat cortical astrocytes. Glia 1994;12:35-43.
30. Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 2009;64:12-21.
31. Valk J, Barkhof F, Scheltens P. Magnetic resonance in dementia. Berlin Heidelberg: Springer-Verlag, 2002.
32. Kruse B, Hanefeld F, Christen HJ, et al. Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol 1993;241:68-74.
33. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128 (Pt 5):1016-25.
34. Jensen JE, Frederick Bde B, Renshaw PF. Grey and white matter GABA level differences in the human brain using two-dimensional, J-resolved spectroscopic imaging. NMR Biomed 2005;18:570-6.
35. Jensen JE, Frederick BD, Wang L, et al. Two-dimensional, J-resolved spectroscopic imaging of GABA at 4 Tesla in the human brain. Magn Reson Med 2005;54:783-8.
36. Prichard J. What the clinician can learn from MRS lactate measurements [review]. NMR Biomed 1991;4:99-102.
37. Barkovich A, Good W, Koch T, et al. Mitochondrial disorders: analysis of their clinical and imaging characteristics. AJNR: Am J Neuroradiol 1993;14:1119-37.
38. Chemelli A, Schocke M, Sperl W, et al. Magnetic resonance spectroscopy (MRS) in five patients with treated propionic acidemia. J Magn Reson Imaging 2000;11:596-600.
39. Petroff O, Graham G, Blamire A, et al. Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes. Neurology 1992;42:1349-54.
40. Felber S, Aichner F, Sauter R, et al. Combined magnetic resonance imaging and proton resonance spectroscopy of patients with acute stroke. Stroke 1992;23:1106-10.
41. Ross BD, Bluml S. New aspects of brain physiology. NMR Biomed 1996;9:279-96.
42. Sylvain M, Arnold DL, Scriver CR, et al. Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin. Pediatr Neurol 1994;10:228-32.
43. Cecil KM. MR spectroscopy of metabolic disorders. Neuroimaging Clin N Am 2006;16:87-116, viii.
44. Willemsen MA, Van Der Graaf M, Van Der Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sjogren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004;25:649-57.
45. Adalsteinsson E, Sullivan EV, Mayer D, et al. In vivo quantification of ethanol kinetics in rat brain. Neuropsychopharmacology 2006;31:2683-91.
46. Lin A, Nguy CH, Shic F, et al. Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy. Toxicol Lett 2001;123:169-77.
47. Mountford C, Stanwell P, Lin A, et al. Neurospectroscopy: the past, present and future. Chem Rev 2010;110:3060-85.
48. Barker P, Lim D. MR spectroscopy of the human brain. Prog Nucl Magn Reson Spectrosc 2006;49:99-128.
49. Lentz M, Taylor J, Feldman D, et al. Current clinical applications of in vivo magnetic resonance spectroscopy and spectroscopic imaging. Curr Med Imaging Rev 2005;1:271-301.
50. Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol 2010;9:94-104.
51. Moonen CT, von Kienlin M, van Zijl PC, et al. Comparison of single-shot localization methods (STEAM and PRESS) for in vivo proton NMR spectroscopy. NMR Biomed 1989;2:201-8.
52. Yongbi NM, Payne GS, Collins DJ, et al. Quantification of signal selection efficiency, extra volume suppression and contamination for ISIS, STEAM and PRESS localized 1H NMR spectroscopy using an EEC localization test object. Phys Med Biol 1995;40:1293-303.
53. Schulte RF, Le Roux P, Vogel MW, et al. Design of phase-modulated broadband refocusing pulses. J Magn Reson 2008;190:271-9.
54. Scheenen TW, Klomp DW, Wijnen JP, et al. Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses. Magn Reson Med 2008;59:1-6.
55. De Stefano N, Filippi M, Miller D, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007;69:1942-52.
56. Adachi M, Hosoya T, Yamaguchi K, et al. Diffusion-and T2-weighted MRI of the transverse pontine fibres in spinocerebellar degeneration. Neuroradiology 2000;42:803-9.
57. Davie C, Barker G, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-92.
58. Haase A, Frahm J, Hanicke W, et al. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985;30:341-4.
59. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-9.
60. Danielsen E, Ross B. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: Marcel Dekker, 1999.
61. Vion-Dury J, Salvan AM, Cozzone PJ. Proton magnetic resonance spectrometry for the non-invasive exploration of human brain metabolism: current and future clinical applications. Rev Neurol 1999;155:903-26.
62. Mascalchi M, Brugnoli R, Guerrini L, et al. Single-voxel long TE 1H-MR spectroscopy of the normal brainstem and cerebellum. J Magn Reson Imaging 2002;16:532-27.
63. Perez-Ruiz A, Julia-Sape M, Mercadal G, et al. The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses. BMC Bioinformatics 2010;11:581.
64. Soher BJ, Hurd RE, Sailasuta N, et al. Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference. Magn Reson Med 1996;36:335-9.
65. Michaelis T, Merboldt K, Bruhn H, et al. Absolute concentrations of metabolites in the adult brain in vivo: quantification of localised proton MR spectra. Radiology 1993;187:219-27.
66. Schirmer T, Auer D. On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain. NMR Biomed 2000;13:28-36.
67. van der Knaap MS, Valk J. MR imaging of the various stages of normal myelination during the first year of life. Neuroradiology 1990;31:459-70.
68. Hetherington HP, Mason GF, Pan JW, et al. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. Magn Reson Med 1994;32:565-71.
69. Haga K, Khor Y, Farrall A, et al. A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol Aging 2009;30:353-63.
70. Gujar S, Maheshwari S, Bjorkman-Burtscher I, et al. Magnetic Resonance Spectroscopy. J Neuroophthalmol 2005;25:217-26.
71. Guerrini L, Belli G, Mazzoni L, et al. Impact of cerebrospinal fluid contamination on brain metabolites evaluation with 1H-MR spectroscopy: a single voxel study of the cerebellar vermis in patients with degenerative ataxias. J Magn Reson Imaging 2009;30:11-17.
72. Pouwels P, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localised proton MRS. Magn Reson Med 1998;39:53-60.
73. McRobbie D, Moore E, Graves M, et al. It's not just squiggles: in vivo spectroscopy. In: McRobbie D, Moore E, Graves M, et al., eds. MRI from picture to proton. 2nd edn. Cambridge: Cambridge University Press, 2007:306-25.
74. Di Costanzo A, Trojsi F, Tosetti M, et al. Proton MR spectroscopy of the brain at 3 T: an update. Eur Radiol 2007;17:1651-62.
75. Gonen O, Gruber S, Li BS, et al. Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal-to-noise ratio and resolution comparison. AJNR Am J Neuroradiol 2001;22:1727-31.
76. Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 2001;45:765-9.
77. Xu D, Chen AP, Cunningham C, et al. Spectroscopic imaging of the brain with phased-array coils at 3.0 T. Magn Reson Imaging 2006;24:69-74.
78. Gruber S, Mlynarik V, Moser E. High-resolution 3D proton spectroscopic imaging of the human brain at 3 T: SNR issues and application for anatomy-matched voxel sizes. Magn Reson Med 2003;49:299-306.
79. Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993;30:424-37.
80. Kantarci K, Reynolds G, Petersen RC, et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3T. AJNR Am J Neuroradiol 2003;24:843-9.
81. Inglese M, Spindler M, Babb JS, et al. Field, coil, and echo-time influence on sensitivity and reproducibility of brain proton MR spectroscopy. AJNR Am J Neuroradiol 2006;27:684-8.
82. Kreis R. Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004;17:361-81.
83. Bottomley P. The trouble with spectroscopy papers. Radiology 1991;181:344-50.
84. Marino S, Ciurleo R, Bramanti P, et al. 1H-MR spectroscopy in traumatic brain injury. Neurocrit Care 2011;14:127-33.
85. de Vries LS, Groenendaal F. Patterns of neonatal hypoxic-ischaemic brain injury. Neuroradiology 2010;52:555-66.
86. Richardson M. Update on neuroimaging in epilepsy. Expert Rev Neurother 2010;10:961-73.
87. Sajja BR, Wolinsky JS, Narayana PA. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2009;19:45-58.
88. Mader I, Rauer S, Gall P, et al. (1)H MR spectroscopy of inflammation, infection and ischemia of the brain. Eur J Radiol 2008;67:250-7.
89. Callot V, Galanaud D, Le Fur Y, et al. (1)H MR spectroscopy of human brain tumours: a practical approach. Eur J Radiol 2008;67:268-74.
90. Elias AE, Carlos RC, Smith EA, et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol 2011;18:1101-8.
91. Leclerc X, Huisman TA, Sorensen AG. The potential of proton magnetic resonance spectroscopy (1)H-MRS) in the diagnosis and management of patients with brain tumors. Curr Opin Oncol 2002;14:292-8.
92. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906-20.
93. Nelson SJ, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002;16:464-76.
94. Hollingworth W, Medina LS, Lenkinski RE, et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 2006;27:1404-11.
95. Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988;38:1371-4.
96. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993;79:533-6.
97. Perez-Cruet MJ, Adelman L, Anderson M, et al. CT-guided stereotactic biopsy of nonenhancing brain lesions. Stereotact Funct Neurosurg 1993;61:105-17.
98. Mihara F, Numaguchi Y, Rothman M, et al. Non-enhancing supratentorial malignant astrocytomas: MR features and possible mechanisms. Radiat Med 1995;13:11-17.
99. Barker FG II, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936-41.
100. Scott JN, Brasher PM, Sevick RJ, et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59:947-9.
101. Ginsberg LE, Fuller GN, Hashmi M, et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436-40.
102. Zeng Q, Liu H, Zhang K, et al. Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy. Magn Reson Imaging 2011;29:25-31.
103. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223-32.
104. Warren KE. NMR spectroscopy and pediatric brain tumors. Oncologist 2004;9:312-18.
105. Kugel H, Heindel W, Ernestus RI, et al. Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 1992;183:701-9.
106. Morita N, Harada M, Otsuka H, et al. Clinical Application of MR Spectroscopy and Imaging of Brain Tumor. Magn Reson Med Sci 2010;9:167-75.
107. Rossi A, Gandolfo C, Morana G, et al. New MR sequences (diffusion, perfusion, spectroscopy) in brain tumours. Pediatr Radiol 2010;40:999-1009.
108. Herminghaus S, Pilatus U, Moller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002;15:385-92.
109. Shimizu H, Kumabe T, Shirane R, et al. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000;21:659-65.
110. Senft C, Hattingen E, Pilatus U, et al. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 2009;65:908-13; discussion 13.
111. Shukla-Dave A, Gupta RK, Roy R, et al. Prospective evaluation of in vivo proton MR spectroscopy in differentiation of similar appearing intracranial cystic lesions. Magn Reson Imaging 2001;19:103-10.
112. Hall WA, Martin A, Liu H, et al. Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. J Magn Reson Imaging 2001;13:12-15.
113. Tate AR, Underwood J, Acosta DM, et al. Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 2006;19:411-34.
114. Rijpkema M, Schuuring J, van der Meulen Y, et al. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging. NMR Biomed 2003;16:12-18.
115. Moreno-Torres A, Martinez-Perez I, Baquero M, et al. Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to noninvasive differential diagnosis with cerebellar astrocytoma. Neurosurgery 2004;55:824-9; discussion 9.
116. Opstad KS, Murphy MM, Wilkins PR, et al. Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 2004;20:187-92.
117. Kimura T, Sako K, Gotoh T, et al. In vivo single-voxel proton MR spectroscopy in brain lesions with ring-like enhancement. NMR Biomed 2001;14:339-49.
118. Chang KH, Song IC, Kim SH, et al. In vivo single-voxel proton MR spectroscopy in intracranial cystic masses. AJNR Am J Neuroradiol 1998;19:401-5.
119. Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005;185:1471-6.
120. Zeng QS, Li CF, Zhang K, et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007;84:63-9.
121. Murphy PS, Viviers L, Abson C, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90:781-6.
122. Lichy MP, Plathow C, Schulz-Ertner D, et al. Follow-up gliomas after radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic accuracy. Neuroradiology 2005;47:826-34.
123. Alexander A, Murtha A, Abdulkarim B, et al. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006;29:301-11.
124. Prat R, Galeano I, Lucas A, et al. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci 2010;17:50-3.
125. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67.
126. Soher BJ, Vermathen P, Schuff N, et al. Short TE in vivo (1)H MR spectroscopic imaging at 1.5 T: acquisition and automated spectral analysis. Magn Reson Imaging 2000;18:1159-65.
127. Soher BJ, Doraiswamy PM, Charles HC. A review of 1H MR spectroscopy findings in Alzheimer's disease. Neuroimaging Clin N Am 2005;15:847-52, xi.
128. Miller BL, Moats RA, Shonk T, et al. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993;187:433-7.
129. Mandal P. Magnetic resonance spectroscopy (MRS) and its application in Alzheimer's disease. Concepts Magn Reson Part A 2007;30A:40-64.
130. Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008;248:210-20.
131. Webster B, Hansen L, Adame A, et al. Astroglial activation of extracellularregulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol 2006;65:142-51.
132. Yang D, Xie Z, Stephenson D, et al. Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). Neuroimage 2011;54:2652-8.
133. Metastasio A, Rinaldi P, Tarducci R, et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 2006;27:926-32.
134. den Heijer T, Sijens PE, Prins ND, et al. MR spectroscopy of brain white matter in the prediction of dementia. Neurology 2006;66:540-4.
135. Hadjivassiliou M, Sanders D, Woodroofe N, et al. Gluten ataxia. Cerebellum 2008;7:494-8.
136. Hadjivassiliou M, Sanders D, Grunewald R, et al. Gluten sensitivity: from gut to brain. Lancet Neurol 2010;9:318-30.
137. Wilkinson I, Hadjivassiliou M, Dickson J, et al. Cerebellar abnormalities on proton MR spectroscopy in gluten ataxia. J Neurol Neurosurg Psychiatry 2005;76:1011-13.
138. Mascalchi M, Cosottini M, Lolli F, et al. Proton MR Spectroscopy of the cerebellum and pons in patients with degenerative ataxia. Radiology 2002;223:371-8.
139. Hennig J, Pfister H, Ernst T, et al. Direct absolute quantification of metabolites in the human brain with in vivo localised proton spectroscopy. NMR Biomed 1992;5:193-9.
140. Dydak U, Pruessmann KP, Weiger M, et al. Parallel spectroscopic imaging with spin-echo trains. Magn Reson Med 2003;50:196-200.
141. Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-47.